Organisation paid for research Program year 2024 Source: CMS Open Payments

Columbus Memory Center PC

Neither a doctor nor a teaching hospital

Research payments

$2,549,343

55 payments

Through program year 2024, Columbus Memory Center PC is reported as receiving $2,549,343 in research payments, across 55 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $14 2
2023 Research $83,390 7
2022 Research $1,527,334 8
2021 Research $742,579 19
2020 Research $142,132 12
2019 Research $53,894 7

Breakdown

Who paid Research payments · program years 2019–2024
  1. Eli Lilly and Company $2,371,778 20 payments
  2. Genentech, Inc. $168,548 33 payments
  3. Novartis Pharmaceuticals Corporation $9,017 2 payments
Studies the money was for Research payments · program years 2019–2024
  1. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $1,183,508 5 payments
  2. A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-Avwa in Participants With Early Symptomatic Alzheimer's Disease $994,030 4 payments
  3. Gantenerumab in Early Ad $168,548 33 payments
  4. Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $110,841 3 payments
  5. Assessment of Safety Tolerability and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $58,934 2 payments
  6. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $23,762 2 payments
  7. A Randomized Double Blind Placebo Controlled Parallel Group Study to Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad $8,862 1 payment
  8. A Phase 3 Open-Label Parallel-Group 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-Avwa in Participants With Early Symptomatic Alzheimer's Disease $515 2 payments
  9. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $178 1 payment
  10. A 5 Year Prospective Study of An Anti Amyloid Therapy Cad106 Or Cnp520 in Slowing and Or Postponing Cognitive Decline in Asymptomatic Apoe 4 Homozygotes at Risk for Developing Alzheimers Disease Dementia $155 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record